Glucagon-like peptide 1 receptor agonist is more efficacious than insulin glargine for poorly controlled type 2 diabetes: a systematic review and meta-analysis

GLP-1RA showed greater efficacy compared to IGlar for type 2 diabetes, and it may also prove beneficial for other diabetes-associated characteristics, including obesity, hypertension, and hyperlipidaemia (Journal of Diabetes)